BMY
WAITBristol-Myers Squibb Company
$63.10
-0.79%delayed
News – · Trend ▲ · below put trigger ▼
Expected move (1d)
▼ $61.59to$64.61 ▲
ATR ±$1.51 (+2.40%)Implied ±$2.45 (+3.88%)
Entry Reference
Price / prev close$63.10 / $63.60
Day range$63.10 – $63.91
52-wk range$42.52 – $64.97(92%)
Volume vs avg0.65×
ATR (14d)$1.51
MA 8 / 21$61.84 / $59.57
MA 50 / 200$57.83 / $55.35
Call ▲ / Put ▼ trigger$63.96 / $63.24
+1 / +2 ATR$64.61 / $66.13
-1 / -2 ATR$61.59 / $60.07
Support: 62.89 62.23 60.78
Resistance: -
Near-the-money contracts
exp 2026-07-31Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 61 | $2.81 | 68% | 0.77 | -0.26 | 1650 |
| 62 | $2.13 | 67% | 0.66 | -0.31 | 1329 |
| 63 | $1.31 | 55% | 0.53 | -0.28 | 1699 |
| 64 | $0.85 | 54% | 0.36 | -0.26 | 585 |
| 65 | $0.54 | 55% | 0.23 | -0.21 | 600 |
| 66 | $0.37 | 58% | 0.14 | -0.16 | 466 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 60 | $0.24 | 54% | -0.09 | -0.10 | 2620 |
| 61 | $0.41 | 52% | -0.17 | -0.16 | 236 |
| 62 | $0.68 | 50% | -0.30 | -0.22 | 1781 |
| 63 | $1.14 | 52% | -0.47 | -0.25 | 111 |
| 64 | $1.77 | 55% | -0.63 | -0.25 | 127 |
| 66 | $3.50 | 71% | -0.81 | -0.23 | 1 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- The Real Price of AbbVie Stock Is Cheaper Than You Think4h ago
- Bristol Myers Squibb (BMY) Stock May Be 48% Below Fair Value On Fresh AI Drug Discovery News6h ago
- Apple Could Swing $170 Billion In Value After Earnings6h ago
- Pfizer Stock Ahead of Q2 Earnings: To Buy or Not to Buy?6h ago
- Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow8h ago
- Bristol-Myers Squibb Stock: Analyst Estimates & Ratings9h ago
- Higher Earnings Forecasts and Opdivo Combo Filing Might Change The Case For Investing In Bristol-Myers Squibb (BMY)12h ago
- BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.12h ago
- Replimune Is Locked in a Standoff With Regulators. Here Is What It Means for the Stock.1d ago
- This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock?1d ago
- Replimune shares fall after FDA reviewers raise doubts over RP1 melanoma drug efficacy1d ago
- Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?1d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.